Skip to content
Q1 '26Q4 '25Q3 '25Q2 '25Q1 '25
Returns
Return on equity-33.6%+21.5pp-30.2%+22.4pp-36.9%+22.8pp-35.7%+12.3pp-55.1%-16.6pp
Return on assets-31.8%+19.2pp-28.1%+19.7pp-34.2%+19.6pp-33.5%+10.8pp-51%-16.6pp
Return on invested capital-45%+27.5pp-42.6%+44.6pp-57.8%+30.5pp-75.3%-12.5pp-72.5%-22.0pp
Liquidity
Current ratio24.8×+9.4×19.7×+9.2×21.9×+14.6×22.4×+11.7×15.4×+0.8×
Quick ratio24.8×+9.4×19.7×+9.2×21.9×+14.6×22.4×+11.7×15.4×+0.8×
Cash ratio2.7×-0.1×1.9×-1.3×6.3×+4.5×12.7×+10.7×2.8×+0.2×
Leverage
Debt-to-equity0.0×0.0×0.0×0.0×0.0×
Debt-to-assets0.0×0.0×0.0×0.0×0.0×
Per Share
Book value per share$1.18+39.8%$1.36+39.2%$1.31+125%$1.52+133%$0.85+16.3%
Valuation
Market capitalization$1.53B+152%$1.61B+336%$1.11B+230%$702.53M+137%$608.13M+77.2%
Enterprise value$1.51B+157%$1.59B+374%$1.06B+228%$586.36M+106%$589.71M+78.3%
Price / book8.9×+2.8×8.8×+5.1×5.9×+0.1×3.5×-0.9×6.1×+1.4×
Earnings yield-3%+4.8pp-2.7%+10.3pp-4.1%+9.0pp-6.7%+6.3pp-7.8%+2.0pp

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where do Trevi Therapeutics, Inc.'s ratios come from?
Every ratio is computed from Trevi Therapeutics, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.